Epigenetics is an exciting area of molecular biology that identifies key changes in gene activity that do not involve changes to the underlying genetic code. Epigenetic “markers” tell genes to switch on or off, to speak loudly or whisper. It is through these epigenetic markers that environmental factors like diet, stress and prenatal nutrition can make an imprint on genes (DNA methylation) that are passed from one generation to the next. Some of these DNA methylation imprints can turn a healthy cell into a cancer cell.
We believe that our proprietary, accurate and scalable epigenetic-based as well as RNA-based technologies provide a key competitive advantage in the diagnosis, prognosis and management of cancer. In addition to our ongoing and planned studies for our tests to assess the risk of aggressive prostate cancer (SelectMDx and ConfirmMDx) and bladder cancer (AssureMDx), our product pipeline includes also tests for kidney cancer and other urological cancers.
MDxHealth’s US headquarters are located in Irvine, California. The European Headquarters recently moved to the Novio Tech Campus in Nijmegen. Here we have completed build-out and certification (ISO 13485-2016) of our state-of-the-art laboratory facilities, significantly expanding our capacity and infrastructure to perform our commercial tests and clinical studies, as well as ongoing research and development.